Abstract
The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Current Pharmaceutical Design
Title: The Urokinase Receptor in Hematopoietic Stem Cells Mobilization
Volume: 17 Issue: 19
Author(s): Francesco Blasi
Affiliation:
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Abstract: The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Export Options
About this article
Cite this article as:
Blasi Francesco, The Urokinase Receptor in Hematopoietic Stem Cells Mobilization, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718206
DOI https://dx.doi.org/10.2174/138161211796718206 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Current Molecular Medicine Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Regulation of Cellular Transport by Klotho Protein
Current Protein & Peptide Science Protein Aggregation and Its Consequences for Human Disease
Protein & Peptide Letters Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins
Mini-Reviews in Medicinal Chemistry Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents